Protagenic Therapeutics effects 1-for-14 reverse stock split to meet Nasdaq bid price rule

Protagenic Therapeutics, Inc.new

Reverse stock split at 1-for-14 ratio effective 12:01 a.m. ET on May 5, 2025.
Approved by stockholders at April 18, 2025 special meeting; board set ratio to comply with Nasdaq Rule 5550(a)(2).
Common stock trades on Nasdaq under symbol PTIX with new CUSIP 74365N301; warrants continue under PTIXW.
Fractional shares rounded up; proportionate adjustments to outstanding options, warrants, and RSUs.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Protagenic Therapeutics, Inc.new: Approved and filed a certificate of amendment to effect a 1-for-14 reverse stock split of common stock (effective 2025-05-05).

Change: charter amendment
Effective: 2025-05-05

Exact text from the filing

On May 2, 2025, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its third amended and restated certificate of incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.

View on SEC.gov

Browse all governance changes →

Protagenic Therapeutics, Inc.new filing history →

Source: SEC EDGAR

accession 0001641172-25-008455

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.